Summary:

In this issue, Dietrich, Trub, and colleagues describe and characterize a novel selective CDK2 inhibitor: INX-315. This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor–resistant breast cancers.

See related article by Dietrich et al., p. 446 (8).

You do not currently have access to this content.